



Dedicated To Life

March 28, 2023

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed copy of two press releases, both dated March 28, 2023, titled (1) **“Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection”** and (2) **“Zydus receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules”**.

The contents of the press releases give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection

Ahmedabad, India, 28 March, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as “Zydus”) has received final approval for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA).

Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st December 2022)



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : ‘Zydus Corporate Park’,
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

Zydus receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules

Ahmedabad, India, 28 March, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as “Zydus”) has received final approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (USRLD: Sinequan[®] Capsules) from the United States Food and Drug Administration (USFDA).

Doxepin Hydrochloride capsule is recommended for the treatment of Psychoneurotic patients with depression and/or anxiety, Depression and/or anxiety associated with alcoholism and organic disease, and Psychotic depressive disorders with associated anxiety including involuntal depression and manic-depressive disorders. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg had annual sales of USD 28.9 mn in the United States (IQVIA MAT Jan. 2023).

The group now has 355 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st December 2022)



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : ‘Zydus Corporate Park’,
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878